Evidence map›Paper›PMID 28334007›Full record

ArticlePloS one2017

A functional variant in NEPH3 gene confers high risk of renal failure in primary hematuric glomerulopathies. Evidence for predisposition to microalbuminuria in the general population.

Konstantinos Voskarides, Charalambos Stefanou, Myrtani Pieri, Panayiota Demosthenous, Kyriakos Felekkis, Maria Arsali, Yiannis Athanasiou, Dimitris Xydakis, Kostas Stylianou, Eugenios Daphnis and 16 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. The 2019 and 2021 International Workshops on Alport Syndrome.European journal of human genetics : EJHG · 2022
    Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. The Hypomorphic Variant p.(Gly624Asp) inFrontiers in pediatrics · 2019
    Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 12 institutions in 6 countries.

Konstantinos VoskaridesDepartment of Biological Sciences and Molecular Medicine Research Center, University of Cyprus, Nicosia, Cyprus.
Charalambos StefanouDepartment of Biological Sciences and Molecular Medicine Research Center, University of Cyprus, Nicosia, Cyprus.
Myrtani PieriDepartment of Biological Sciences and Molecular Medicine Research Center, University of Cyprus, Nicosia, Cyprus.
Panayiota DemosthenousDepartment of Biological Sciences and Molecular Medicine Research Center, University of Cyprus, Nicosia, Cyprus.
Kyriakos FelekkisDepartment of Biological Sciences and Molecular Medicine Research Center, University of Cyprus, Nicosia, Cyprus.
Maria ArsaliDepartment of Nephrology, Limassol General Hospital, Limassol, Cyprus.
Yiannis AthanasiouDepartment of Nephrology, Nicosia General Hospital, Nicosia, Cyprus.
Dimitris XydakisDepartment of Nephrology, University of Crete, Heraklion, Crete, Greece.
Kostas StylianouDepartment of Nephrology, University of Crete, Heraklion, Crete, Greece.
Eugenios DaphnisDepartment of Nephrology, University of Crete, Heraklion, Crete, Greece.
Giorgos GoulielmosDepartment of Internal Medicine, Section of Molecular Medicine and Human Genetics, Medical School, University of Crete, Heraklion, Greece.
Petros LoizouPrivate Clinical Laboratory, Paralimni, Cyprus.
Judith SavigeDepartment of Medicine, The University of Melbourne, Northern Health, Epping, Australia.
Martin HöhneDepartment 2 of Internal Medicine and Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany.
Linus A VölkerDepartment 2 of Internal Medicine and Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany.
Thomas BenzingDepartment 2 of Internal Medicine and Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany.
Patrick H MaxwellDivision of Medicine, University College London, London, United Kingdom.
Daniel P GaleUCL Centre for Nephrology, University College London, London, United Kingdom.
Mathias GorskiDepartment of Nephrology, University Hospital Regensburg, Regensburg, Germany.
Carsten BögerDepartment of Nephrology, University Hospital Regensburg, Regensburg, Germany.
Barbara KolleritsDivision of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Innsbruck Medical University, Innsbruck, Austria.
Florian KronenbergDivision of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Innsbruck Medical University, Innsbruck, Austria.
Bernhard PaulweberFirst Department of Internal Medicine, Paracelsus Private Medical University Salzburg, Salzburg, Austria.
Michalis ZavrosDepartment of Nephrology, Nicosia General Hospital, Nicosia, Cyprus.
Alkis PieridesDepartment of Nephrology, Hippocrateon Hospital, Nicosia, Cyprus.
Constantinos DeltasDepartment of Biological Sciences and Molecular Medicine Research Center, University of Cyprus, Nicosia, Cyprus.
University of Cyprus · CYUniversity of Crete · GRInnsbruck Medical University · ATNicosia General Hospital · CYUniversity College London · GBUniversity Hospital Regensburg · DEUniversity of Cologne · DECologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases · DEHippocrateon Private Hospital · CYLimassol General Hospital · CYNorthern Health · AUParacelsus Medical University · AT

Funding

THE FRAMINGHAM HEART STUDY-N01HC25195-268025195-268025195N01HC025195 · HC · TRUSTEES OF BOSTON UNIVERSITY · PI WOLF, PHILIP A · 2002 to 2006
–
Medical Research Council G1002528NHLBI NIH HHS N01 HC025195
6 · The paper itself

Abstract

backgroundRecent data emphasize that thin basement membrane nephropathy (TBMN) should not be viewed as a form of benign familial hematuria since chronic renal failure (CRF) and even end-stage renal disease (ESRD), is a possible development for a subset of patients on long-term follow-up, through the onset of focal and segmental glomerulosclerosis (FSGS). We hypothesize that genetic modifiers may explain this variability of symptoms.

methodsWe looked in silico for potentially deleterious functional SNPs, using very strict criteria, in all the genes significantly expressed in the slit diaphragm (SD). Two variants were genotyped in a cohort of well-studied adult TBMN patients from 19 Greek-Cypriot families, with a homogeneous genetic background. Patients were categorized as "Severe" or "Mild", based on the presence or not of proteinuria, CRF and ESRD. A larger pooled cohort (HEMATURIA) of 524 patients, including IgA nephropathy patients, was used for verification. Additionally, three large general population cohorts [Framingham Heart Study (FHS), KORAF4 and SAPHIR] were used to investigate if the NEPH3-V353M variant has any renal effect in the general population. RESULTS AND

conclusionsGenotyping for two high-scored variants in 103 TBMN adult patients with founder mutations who were classified as mildly or severely affected, pointed to an association with variant NEPH3-V353M (filtrin). This promising result prompted testing in the larger pooled cohort (HEMATURIA), indicating an association of the 353M variant with disease severity under the dominant model (p = 3.0x10-3, OR = 6.64 adjusting for gender/age; allelic association: p = 4.2x10-3 adjusting for patients' kinships). Subsequently, genotyping 6,531 subjects of the Framingham Heart Study (FHS) revealed an association of the homozygous 353M/M genotype with microalbuminuria (p = 1.0x10-3). Two further general population cohorts, KORAF4 and SAPHIR confirmed the association, and a meta-analysis of all three cohorts (11,258 individuals) was highly significant (p = 1.3x10-5, OR = 7.46). Functional studies showed that Neph3 homodimerization and Neph3-Nephrin heterodimerization are disturbed by variant 353M. Additionally, 353M was associated with differential activation of the unfolded protein response pathway, when overexpressed in stressed cultured undifferentiated podocyte cells, thus attesting to its functional significance. Genetics and functional studies support a "rare variant-strong effect" role for NEPH3-V353M, by exerting a negative modifier effect on primary glomerular hematuria. Additionally, genetics studies provide evidence for a role in predisposing homozygous subjects of the general population to micro-albuminuria.

Indexed as

AdultAlbuminuriaFemaleGenetic Predisposition to DiseaseHEK293 CellsHematuriaHumansImmunoblottingImmunoglobulinsImmunoprecipitationKidney Failure, ChronicMaleMembrane ProteinsMiddle AgedPolymorphism, Single NucleotideRenal InsufficiencyImmunoglobulinsKIRREL2 protein, humanMembrane Proteins

Identifiers

PMID28334007
PMCPMC5363870
OpenAlexW2602871570

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.